Posted on

Article: Form S-1/A Bionano Genomics, Inc

Article - Media, Publications

Form S-1/A Bionano Genomics, Inc

EDGARFILINGS LTD, 17 October 2020

We are offering 5,265,000 shares of our common stock and common warrants to purchase an aggregate of 5,265,000 shares of our common stock (and the shares of common stock that are issuable from time to time upon exercise of the warrants). We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. Continue reading “Article: Form S-1/A Bionano Genomics, Inc”

Posted on

Article: Wirecard’s suspect accounting practices revealed

Article - Media

Wirecard’s suspect accounting practices revealed

Dan McCrum

Financial Times, 15 October 2019

FT Investigation: internal documents from the payments company point to a concerted effort to fraudulently inflate sales and profits

Comment: Dan McCrum is strongly suspected of being a shill for naked short sellers, and appears to be one of several journalists — others work for the Wall Street Journal — who routinely bash companies to further illegal naked short selling campaign.  He should be deeply investigated.

Posted on

Article: Bausch Health jumps after short seller says stock could double

Article - Media, Publications

Bausch Health jumps after short seller says stock could double

Cristin Flanagan, 15 October 2019

Shares of Bausch Health Cos. jumped as much as 5.5 per cent intraday after a short-seller changed his tune and said the stock could nearly double. Also, Bausch shed another bear as Wells Fargo realigned its coverage. Andrew Left’s Citron Research set a price target of US$40, more than 80 per cent above current trading. The report comes more than four years after the short-seller’s 2015 call, when Left accused Bausch, then known as Valeant Pharmaceuticals, of being “Enron part deux.”

Bausch shares have come down more than 90 per cent from 2015. The stock “still trades with a ‘Valeant discount’ despite new management’s 180-degree turn,” the Citron report said. Bausch’s Nov. 4 earnings may be when Wall Street finally takes notice, it added.
Continue reading “Article: Bausch Health jumps after short seller says stock could double”

Posted on

Article: Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’

Article - Media, Publications

Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’

Wayne Duggan, 15 October 2019

Three years after Citron Research called Valeant the “pharmaceutical Enron,” the firm said Tuesday that it’s time to give Valeant successor Bausch Health Companies Inc BHC 0.06% the credit it is due for its rebranding and turnaround efforts.

On Tuesday, Citron Research’s Andrew Left said CEO Joe Papa has done a spectacular job since taking over less than four years ago. In the past three years alone, management has paid down about $8 billion in debt, vastly improving the company’s balance sheet and putting them in a position of financial flexibility.

“In 2019, the debt has become manageable and the company is gaining momentum with recent, successful launches of new drugs, consistent with its ‘pivot to offense,’” Left said.
Continue reading “Article: Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’”

Posted on

Article: BAUSCH HEALTH – THE TEXTBOOK TURNAROUND Giving Credit Where Credit is Due – Target Price $40

Article - Media, Publications

BAUSCH HEALTH – THE TEXTBOOK TURNAROUND Giving Credit Where Credit is Due – Target Price $40

Citron Research, 15 October 2019

It was four years ago this month that Citron wrote a series of articles that were instrumental in the unraveling of the Pearson-era Valeant business model. In quick manner the stock has declined by 90% from its highs as the scandals unraveled and many questioned the sustainability of the equity.

Four years later BHC still trades with a “Valeant discount” despite new management’s 180-degree turn of corporate culture. To add to the artificially depressed share price, Bausch has been unjustly grouped with Specialty Pharma despite having ZERO opioid exposure and minimal exposure to the generics market.

Citron believes this quarter (reporting on Nov 4) will force Wall St. to finally take notice of BHC’s “pivot to offense”. Once this is considered along with the acknowledgment of the recent M&A spree in pharma, even David Maris will have to admit that BHC is on its way to $40.
Continue reading “Article: BAUSCH HEALTH – THE TEXTBOOK TURNAROUND Giving Credit Where Credit is Due – Target Price $40”

Posted on

Fined: Dougherty & Company LLC Fined by FINRA

Fined

Dougherty & Company LLC Fined by FINRA

An AWC was issued in which the firm was censured, fined $25,000 and required to revise its written supervisory procedures (WSPs). Without admitting or denying the findings, the firm consented to the sanctions and to the entry of findings that it failed to make timely submissions or to submit accurate information regarding the result of an interest rate reset for variable rate demand obligations to the Municipal Securities Rulemaking Board’s (MSRB) Short-Term Obligation Rate Transparency (SHORT) system.

Read full report.

 

Posted on

Release: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Overstock.com, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – OSTK

Release

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Overstock.com, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – OSTK

9 October 2019

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Overstock.com, Inc. ( OSTK) from May 9, 2019 through September 23, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Overstock investors under the federal securities laws.

Read full release.

Posted on

Release: INVESTOR ALERT Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Overstock.com, Inc. Investors

Release

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Overstock.com, Inc. Investors

8 October 2019

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Overstock.com, Inc. (“Overstock” or the “Company”) (NASDAQ: OSTK) securities between May 9, 2019 and September 23, 2019, inclusive (the “Class Period”). Overstock investors have until November 26, 2019 to file a lead plaintiff motion.

Read full release.

Posted on

Article: Former Overstock CEO Explains by Charles Gasparino and Lydia Moynihan

Article - Media

Fmr. Overstock CEO Patrick Byrne wants to explain controversial exit, stock sale and predicts more deep state revelations

According to Byrne, his departure and stock sale are unrelated to his FBI activities or what he has described as a romantic tryst with an alleged Russian spy, Maria Butina, though he says those matters will become a huge story sometime soon. Byrne in his interview with FOX Business said he didn’t want to dwell on spycraft (“I’m supposed to be keeping quiet [on] all that political stuff,” he said), adding cryptically that the full story “will break this year and it will be 100 times bigger than Watergate … it’s political fraud conducted by the deep state against the republic, against Democrats and Republicans … I was asked to set up Hillary Clinton,” all of which he declined to elaborate on.

Posted on

Fined: ABN AMRO Clearing Chicago LLC Fined by FINRA

Fined

ABN AMRO Clearing Chicago LLC Fined by FINRA

An AWC was issued in which the firm was censured and fined $150,000. Without admitting or denying the findings, the firm consented to the sanctions and to the entry of findings that it understated the portfolio margin requirements for accounts at various points in time. The findings stated that the firm incorrectly treated certain overthe-counter (OTC) equity securities, which are not margin eligible, as marginable securities. As a consequence, the firm understated the margin requirements for these accounts by millions of dollars.

Read full report.

Posted on

Article: CFTC Settles With Morgan Stanley & Mitsubishi, $1.4 & $0.4 Million Fines For Spoofing Gold & Silver

Article - Media

CFTC Settles With Morgan Stanley & Mitsubishi, $1.4 & $0.4 Million Fines For Spoofing Gold & Silver

Ottawa Bullion, 3 October 2019

The U.S. Commodity Futures Trading Commission today announced that civil enforcement actions were filed and simultaneously settled against two trading firms and one bank for violating the Commodity Exchange Act’s (CEA) prohibition on spoofing (bidding or offering with the intent to cancel the bid or offer before execution). These cases were brought in connection with the Division of Enforcement’s Spoofing Task Force.

Read full article.

Posted on

Release: IMPORTANT OVERSTOCK.COM, INC. INVESTOR ALERT Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the District of Utah on behalf of shareholders of Overstock.com, Inc.

Release

IMPORTANT OVERSTOCK.COM, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the District of Utah on behalf of shareholders of Overstock.com, Inc.

2 October 2019

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal class action securities lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Overstock.com, Inc. (“Overstock” or the “Company”) (NASDAQ: OSTK) who purchased shares between May 9, 2019, and September 23, 2019, inclusive (the “Class Period”).

Read full release.

Posted on

Release: LEADING ROSEN LAW FIRM Reminds Infosys Limited Investors of Important Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors With Losses in Excess of $100K to Contact the Firm – INFY

Release

LEADING ROSEN LAW FIRM Reminds Infosys Limited Investors of Important Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors With Losses in Excess of $100K to Contact the Firm – INFY

2 October 2019

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Infosys Limited (NYSE:INFY) from July 7, 2018 and October 20, 2019, inclusive (the “Class Period”) of the important December 23, 2019 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Infosys investors under the federal securities laws.

Read full release.

Posted on

Article: Collusion with Trump over Russia inquiry ‘did not happen’, says Raab

Article - Media, Publications

Collusion with Trump over Russia inquiry ‘did not happen’, says Raab

Patrick Wintour, 02 October 2019

No member of the British government, including the prime minister, would ever collude with Donald Trump to try to discredit the work of intelligence agencies uncovering Russian interference in the 2016 US election, the UK foreign secretary said.

Dominic Raab told the Commons that “any such collusion is entirely unacceptable, would never happen, and did not happen”.

The foreign secretary refused to say at prime minister’s questions whether Boris Johnson, or his predecessor, Theresa May, had spoken to the US president about any request to cooperate with the inquiry he had ordered into how the US intelligence agencies handled claims that Russia colluded with the Trump presidential campaign in 2016.

The collusion claim led to the lengthy report by Robert Mueller, which showed that Russia was attempting to swing the presidential election in favour of Trump but did not say whether there had been collusion between Russia and Trump.

Raab was asked whether, as reported in the Times, Trump had personally contacted Johnson to ask him to cooperate with the US inquiry.

The Labour MP Ben Bradshaw implied that the purpose of any Trump request might be “to undermine or smear British intelligence services, as well as damage cooperation with their US colleagues”.

Raab, deputising for Johnson at prime minister’s questions, said: “Neither the prime minister or, as then, the foreign secretary, would collude in the way that he described. That is entirely unacceptable and would never happen and did not happen.”

It is noticeable that the British government has been less willing than either the Australian or Italian governments to give details of help given to Trump’s inquiry into the role of the US intelligence services.

Read Full Article